{
    "root": "2f749d4b-0101-f271-e063-6294a90ac58c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gabapentin",
    "value": "20250303",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "GABAPENTIN",
            "code": "6CW7F3G59X"
        },
        {
            "name": "D&C RED NO. 33",
            "code": "9DBA0SBB0L"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Gabapentin is indicated for:\n                        \n                           Management of postherpetic neuralgia in adults\n                           Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy",
    "contraindications": "Postherpetic Neuralgia ( 2.1 ) Dose can be titrated up as needed to a dose of 1,800 mg/day Day 1: Single 300 mg dose Day 2: 600 mg/day (i.e., 300 mg two times a day) Day 3: 900 mg/day (i.e., 300 mg three times a day) Epilepsy with Partial Onset Seizures ( 2.2 ) Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 )",
    "warningsAndPrecautions": "Gabapentin capsules, USP are supplied as follows:\n                  100 mg: Capsules, with grey \"100 mg\" imprinted on the white body and grey \"OE B56\" on the white cap. The content is white or off-white powder.\n                  Bottles of 100 with child-resistant closure: NDC83301-0003-1\n                  Bottles of 500: NDC 83301-0003-2\n                  Bottles of 1000: NDC 83301-0003-3\n                  \n                       300 mg: Capsules with grey \"300 mg\" imprinted on the white body and grey \"OE B57\" on the yellow cap. The content is white or off-white powder.\n \n                  Bottles of 100 with child-resistant closure: NDC 83301-0004-1\n                  Bottles of 500: NDC  83301-0004-2\n                  Bottles of 1000: NDC 83301-0004-3\n                  \n                       400 mg: Capsules with grey \"400 mg\" imprinted on the white body and grey \"OE B58\" on the orange cap. The content is white or off-white powder.\n \n                  Bottles of 100 with child-resistant closure: NDC 83301-0005-1\n                  Bottles of 500: NDC  83301-0005-2\n                  Bottles of 1000: NDC 83301-0005-3",
    "adverseReactions": "Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients."
}